Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Original Article

Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study

Moon Haeng Hur, Dong Hyeon Lee, Jeong-Hoon Lee, Mi-Sook Kim, Jeayeon Park, Hyunjae Shin, Sung Won Chung, Hee Jin Cho, Min Kyung Park, Heejoon Jang, Yun Bin Lee, Su Jong Yu, Sang Hyub Lee, Yong Jin Jung, Yoon Jun Kim, Jung-Hwan Yoon

Clin Mol Hepatol. 2024;30(3):500-514. Published online May 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0055

View: 2240 Download: 151

Editorial

Toward hepatitis C virus elimination using artificial intelligence

Moon Haeng Hur, Jeong-Hoon Lee

Clin Mol Hepatol. 2024;30(2):147-149. Published online February 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0135

View: 2353 Download: 77 Crossref: 1

Original Article

Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma

Jeayeon Park, Sung Won Chung, Yun Bin Lee, Hyunjae Shin, Moon Haeng Hur, Heejin Cho, Min Kyung Park, Jeonghwan Youk, Ji Yun Lee, Jeong-Ok Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Tae Min Kim, Jeong-Hoon Lee

Clin Mol Hepatol. 2023;29(3):794-809. Published online May 17, 2023

DOI: https://doi.org/10.3350/cmh.2023.0057

View: 3784 Download: 154 Web of Science: 1 Crossref: 1

Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis

Moon Haeng Hur, Yuri Cho, Do Young Kim, Jae Seung Lee, Gyoung Min Kim, Hyo-Cheol Kim, Dong Hyun Sinn, Dongho Hyun, Han Ah Lee, Yeon Seok Seo, In Joon Lee, Joong-Won Park, Yoon Jun Kim

Clin Mol Hepatol. 2023;29(3):763-778. Published online May 30, 2023

DOI: https://doi.org/10.3350/cmh.2023.0076

View: 3569 Download: 208 Web of Science: 4 Crossref: 6

Editorial

The imitator of immune-tolerant chronic hepatitis B: A killer in disguise

Moon Haeng Hur, Jeong-Hoon Lee

Clin Mol Hepatol. 2023;29(2):363-366. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0079

View: 3109 Download: 95 Web of Science: 2 Crossref: 2

1 |

Viewed By 5157	MAFLD: How is it different from NAFLD?
Viewed By 4901	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4875	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 4590	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 4570	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 219	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 155	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 134	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 119	MAFLD: How is it different from NAFLD?
Cited By 96	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search